NasdaqCM - Delayed Quote • USD
NeuroBo Pharmaceuticals, Inc. (NRBO)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:21 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 3.03M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| WOODWORTH MARSHALL H Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| TURSI JAMES PATRICK Director | -- | Direct | -- | Dec 1, 2023 |
| KIM HYUNG HEON Chief Executive Officer | -- | Direct | -- | Aug 11, 2023 |
| STRICKLAND DAVID GORDON Director | -- | Direct | -- | Jul 27, 2023 |
| KOVEN ANDREW IAN Director | -- | Direct | -- | Jul 27, 2023 |
| GLICKMAN MARK A Director | -- | Direct | -- | Jul 27, 2023 |
| GROVES JASON L Director | -- | Direct | -- | Jul 27, 2023 |
| SALSBURY MICHAEL Director | -- | Direct | -- | Jul 27, 2023 |
| KIM NA YEON Director and Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Jul 27, 2023 |
| BAKSHI AKASH Chief Operating Officer | -- | Indirect | -- | Dec 31, 2020 |
| OH JEONG GYUN Director and Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Dec 30, 2019 |
| KIM NA YEON Director and Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Dec 30, 2019 |
| KOUSKY KENNETH W Director | -- | Direct | -- | Jul 24, 2019 |
| BISGAIER CHARLES L Chairman of the Board | -- | Direct | -- | Jul 24, 2019 |
| LICHTINGER PEDRO Director | -- | Direct | -- | Jul 24, 2019 |
| GULLANS STEVEN R. PH.D Chief Executive Officer | -- | Direct | -- | Jul 24, 2019 |
| RENO SETH Officer | -- | Direct | -- | Jul 24, 2019 |
| SASSINE ANDY H Director | -- | Direct | -- | Jul 24, 2019 |
| GULLANS STEVEN R. PH.D Chief Executive Officer | Purchase at price 7.00 per share. | Indirect | 500,003 | Feb 8, 2018 |
| RENO SETH Officer | Purchase at price 7.00 per share. | Direct | 100,002 | Feb 8, 2018 |
| MATHIESEN JEFFREY S Chief Financial Officer | Conversion of Exercise of derivative security at price 3.59 per share. | Direct | 11,513 | Aug 14, 2017 |
| MATHIESEN JEFFREY S Chief Financial Officer | Conversion of Exercise of derivative security at price 3.59 per share. | Direct | 10,770 | Aug 10, 2017 |
| MATHIESEN JEFFREY S Chief Financial Officer | Conversion of Exercise of derivative security at price 3.59 per share. | Direct | 10,770 | Aug 10, 2017 |
| BISGAIER CHARLES L Chairman of the Board | Conversion of Exercise of derivative security at price 1.34 per share. | Direct | 6,013 | Jul 31, 2017 |
| LICHTINGER PEDRO Director | Purchase at price 9.47 per share. | Direct | 99,994 | Mar 10, 2017 |
| GULLANS STEVEN R. PH.D Director | Purchase at price 9.47 per share. | Indirect | 499,997 | Mar 10, 2017 |
| HAWRYLUK P KENT Director | Purchase at price 9.47 per share. | Indirect | 236,750 | Mar 10, 2017 |
| SASSINE ANDY H Director | Purchase at price 9.47 per share. | Direct | 199,997 | Mar 10, 2017 |
| MATHIESEN JEFFREY S Chief Financial Officer | Purchase at price 10.00 per share. | Direct | 40,000 | Aug 10, 2016 |
| MATHIESEN JEFFREY S Chief Financial Officer | Conversion of Exercise of derivative security at price 6.71 per share. | Direct | 26,334 | Aug 10, 2016 |
| KOUSKY KENNETH W Director | Purchase at price 10.00 per share. | Direct | 10,000 | Aug 10, 2016 |
| KOUSKY KENNETH W Director | Conversion of Exercise of derivative security at price 6.71 per share. | Indirect | 783,859 | Aug 10, 2016 |
| BISGAIER CHARLES L Chairman of the Board | Purchase at price 10.00 per share. | Direct | 517,500 | Aug 10, 2016 |
| BISGAIER CHARLES L Chairman of the Board | Conversion of Exercise of derivative security at price 6.71 per share. | Indirect | 237,201 | Aug 10, 2016 |
| LICHTINGER PEDRO Director | Purchase at price 10.00 per share. | Direct | 100,000 | Aug 10, 2016 |
| LICHTINGER PEDRO Director | Conversion of Exercise of derivative security at price 6.71 per share. | Direct | 263,368 | Aug 10, 2016 |
| GULLANS STEVEN R. PH.D Director | Purchase at price 10.00 per share. | Indirect | 5,000,000 | Aug 10, 2016 |
| GULLANS STEVEN R. PH.D Director | Conversion of Exercise of derivative security at price 6.71 per share. | Indirect | 2,052,173 | Aug 10, 2016 |
| SASSINE ANDREW HEROUX Director | Conversion of Exercise of derivative security at price 0.00 - 6.71 per share. | Direct | 213,603 | Aug 10, 2016 |
| SOOCH MINA PATEL Chief Executive Officer | Purchase at price 10.00 per share. | Direct | 525,000 | Aug 10, 2016 |
| SOOCH MINA PATEL Chief Executive Officer | Conversion of Exercise of derivative security at price 6.71 per share. | Indirect | 182,005 | Aug 10, 2016 |
| RENO SETH Officer | Purchase at price 10.00 per share. | Direct | 40,000 | Aug 10, 2016 |
| ONICIU CARMEN DANIELA Officer | -- | Direct | -- | Aug 10, 2016 |
| HAWRYLUK P KENT Director | Purchase at price 10.00 per share. | Indirect | 250,000 | Aug 10, 2016 |
| HAWRYLUK P KENT Director | Conversion of Exercise of derivative security at price 6.71 per share. | Indirect | 158,367 | Aug 10, 2016 |
| LOWENSCHUSS DAVID H Officer | Purchase at price 10.00 per share. | Direct | 111,200 | Aug 10, 2016 |
| SASSINE ANDY H Director | Conversion of Exercise of derivative security at price 6.71 per share. | Direct | 213,603 | Aug 10, 2016 |
Related Tickers
VRAX Virax Biolabs Group Limited
0.7000
+7.53%
KPRX Kiora Pharmaceuticals, Inc.
0.4800
-5.10%
REVB Revelation Biosciences, Inc.
2.1399
+2.39%
ADTX Aditxt, Inc.
2.5300
+6.75%
ENSC Ensysce Biosciences, Inc.
0.5467
-2.13%
SPRC SciSparc Ltd.
1.2600
+4.13%
VRPX Virpax Pharmaceuticals, Inc.
2.9184
-5.55%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.7600
-2.76%
RNAZ TransCode Therapeutics, Inc.
0.5250
+19.35%
ALGS Aligos Therapeutics, Inc.
0.8180
-1.33%